Exelixis is rated a Sell, with a $41 fair value; at $68.29, shares exceed a $65.57 valuation even if every pipeline program ...
Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated ...
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model ...
Cabozantinib (XL184) Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Castration-Resistant Prostate Cancer High rates of complete or partial bone scan resolution (85%), pain ...
Cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors (NETs), ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
COPENHAGEN — First-line treatment of metastatic kidney cancer could be set for change, with new results showing that the oral tyrosine kinase inhibitor cabozantinib (Cabometyx, Exelixis) significantly ...
Please provide your email address to receive an email when new articles are posted on . The combination of cabozantinib and durvalumab appeared safe and demonstrated efficacy among a small cohort of ...
Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases -- ...
SAN FRANCISCO — Treatment with cabozantinib (Cabometyx, Exelixis) significantly improved outcomes in patients with advanced hepatocellular carcinoma (HCC), leading researchers to suggest that it could ...
The appraisal committee considered evidence submitted by Ipsen, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...